less evidence was found for
raloxifene. the USPSTF found good evidence that both tamoxifen and
raloxifene increase the risk of thromboembolitic events (stroke, DVT, PE). they found that tamoxifen increases the risk of endometrial CA.
the USPSTF recommends screening for colon CA starting at age 50 in men and women. earlier screening recommendations depend on the patient, family history and medical conditions (ie they are different for conditions such as ulcerative colitis, etc).